Regado Biosciences, Inc. And Tobira Therapeutics Inc. Merger Agreement Conference Call Set For 8:30 A.M. EST Today, Jan. 20

SAN FRANCISCO and BASKING RIDGE, N.J., Jan. 20, 2015 /PRNewswire/ -- Regado Biosciences, Inc. (NASDAQ: RGDO) and Tobira Therapeutics, Inc. will conduct a call at 8:30 a.m. EST today, Jan. 20, to discuss the definitive merger agreement announced on Jan. 15, 2015.

Interested participants and investors may access the conference call by dialing (888) 347-1165 for domestic callers or (412) 902-4276 for international callers. The conference call will be webcast live under the investor relations section of the Regado website at www.regadobio.com and will be archived there for 60 days following the call.

About Regado Biosciences

Regado Biosciences, Inc. is a development stage biotechnology company that was engaged in the development of therapies using actively controlled aptamer technology, which is designed to give physicians the ability to control the therapeutic effect in real time. In August, 2014, the Company announced the termination of its Phase 3 REGULATE-PCI study due to safety concerns with its lead drug Revolixys. The Company subsequently announced the planned reorganization of its business and the pursuit of strategic alternatives led by its financial advisors MTS Health Partners and Cowen and Company, LLC. No further development activities are ongoing nor have any been planned for the Regado pipeline.  The final results of the REGULATE-PCI study will be presented at one or more upcoming medical meetings in the first half of 2015. More information can be found at www.regadobio.com.

About Tobira Therapeutics

Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and HIV.  Tobira is actively enrolling patients in a Phase 2b clinical trial called CENTAUR to evaluate CVC in patients with NASH and liver fibrosis. Learn more at www.tobiratherapeutics.com.

Important Information and Where to Find It

Regado and Tobira and certain of their directors and executive officers may become participants in solicitation of proxies from Regado stockholders in connection with the proposed transactions. Additional Information regarding persons who may, under the rules of the SEC, be deemed to be participants in the solicitation of the Regado stockholders in connection with the proposed merger, and who have interests, whether as security holders, directors or employees of Regado or Tobira or otherwise, which may be different from those of Regado stockholders generally, will be provided in the proxy statement and other materials to be filed with the SEC.

Each of Regado's board of directors, Dennis Podlesak, Jeff Clark, Drew Fromkin, Anton Gopka, Pierre Legault, Michael Mendelsohn, P. Sherrill Neff, Jesse Treu and Michael Metzger; Regado's executive officers, Michael Metzger (President and Chief Executive Officer) and Don Elsey (Senior Vice President, Finance and Chief Financial and Compliance Officer); Tobira's board of directors, Eckard Weber, Laurent Fischer, Carol Brosgart, Patrick Heron, Craig Gibbs, Jeffrey Cooper, Dr. Graeme Moyle and Gwen Melincoff; and Tobira's executive officers, Laurent Fischer (Chief Executive Officer), Christopher Peetz (Chief Financial Officer and Secretary), Eric Lefebvre (Chief Medical Officer), Helen Jenkins (Chief Operating Officer), and Martine Kraus (Vice President, Regulatory Affairs); may be deemed "participants" in the solicitation of proxies from the Regado stockholders in connection with the proposed transactions. 

Information regarding the special interests of these directors and executive officers in the merger will be included in the proxy statement referred to above.  Additional information regarding Regado's directors' and executive officers' respective interests in Regado by security holdings or otherwise is set forth in Regado's proxy statement relating to the 2015 annual meeting of stockholders filed with the SEC on May 5, 2014. 

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. A definitive proxy statement and a proxy card will be filed with the SEC and will be mailed to Regado's stockholders seeking any required stockholder approvals in connection with the proposed transactions. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT REGADO MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS. Stockholders may obtain, free of charge, copies of the definitive proxy statement and any other documents filed by Regado with the SEC in connection with the proposed transactions at the SEC's website (http://www.sec.gov), at Regado's website or by writing to the Secretary, Regado, Inc. at 106 Allen Road, Basking Ridge, NJ 07920.  

Tobira Contacts:
Chris Peetz
Chief Financial Officer
Tobira Therapeutics
(650) 351-5018
cpeetz@tobiratherapeutics.com

Mark Corbae
Canale Communications
(619) 849-5375
mark@canalecomm.com

Regado Contacts:
Don Elsey
Chief Financial Officer
Regado Biosciences, Inc.
(908) 580-2113
delsey@regadobio.com

David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/reminder-regado-biosciences-and-tobira-therapeutics-merger-agreement-conference-call-set-for-830-am-est-today-jan-20-300022575.html

SOURCE Regado Biosciences, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news